Any current/future new fundraising through debt or equity?

No explicit mention of any new fundraising through debt or equity in the transcript. The company remains a net debt free company as of March 31, 2024. There is mention of increased growth capital available with the new promoter Nirma Limited, but this refers to internal capital allocation rather than external fundraising. Capex plans are underway, with INR129 crores spent in FY '24 and new capacities starting operations in FY '25. Management focuses on calibrated capacity expansion based on business visibility, using existing resources. No indications or plans disclosed for raising funds throu

Any current/future capex/capital investment/strategic investment?

FY '25 Capex: Around INR340 crores planned. Major part (~INR140 crores) allocated for greenfield site development at Sholapur. Remaining capex to complete brownfield projects at Ankleshwar and Dahej. Regular maintenance, R&D, and quality-related capex also included. Capacity additions planned: ~208 KL at Ankleshwar (Plant 18), ~35 KL in pharma area 4 at Dahej. Sholapur capacity (approx. 500 KL) expected by late FY '26, with phased commissioning. Potential additional 120 KL capacity from Plant 6 in Dahej by mid-2026. Investments targeted at technologies to open higher-value portfolio opportunit

Future growth expectations in sales/revenue/volumes?

Glenmark Life Sciences expects high single-digit growth in Glenmark Pharma (GPL) business from FY '24 base. Overall FY '25 top-line growth is projected at low to mid-teens, supported by a robust external business and expected recovery in the Japanese market. Volume growth is anticipated around 10% to 11% with a price erosion of approximately 4% to 4.5%. The CDMO segment is expected to see revenue growth, with plans to increase the portfolio, aiming for about INR 500-600 crores in 4 years and potentially INR 1,000 crores longer term. Capacity expansions at Ankleshwar and Dahej operation

Future growth expectations in earnings/operating earnings/profits/EPS?

Glenmark Life Sciences expects overall revenue growth in FY '25 to be low to mid-teens percentage, driven by a high single-digit growth in Glenmark business (Generic API) and robust external business including CDMO and Japan market recovery. EBITDA margins are projected in the range of 28% to 30%, considering a 100-150 basis points reduction due to discontinuation of PLI benefits. The company anticipates volume growth of around 10-11%, with a price erosion of 4-4.5%. One-time employee bonus costs, which impacted FY '24 margins, are expected to normalize from Q1 FY '25 onward. Capacity expansio

Current/ Expected Orderbook/ Pending Orders?

Glenmark Life Sciences reports a strong order book for the coming quarters despite recent supply chain disruptions. Demand across most markets remains stable, with the exception of Japan, where inventory destocking is ongoing but expected to recover in H2 FY'25. The company anticipates robust growth in both Generic API and CDMO businesses supported by new capacity additions. There is no explicit quantification of the exact pending order value disclosed in the call. Business visibility typically spans 1 to 2 quarters, allowing capacity to be scaled within approximately 5-6 months when new busin

Alivus Life Sciences LtdQ4 FY24Pharmaceuticals & Biotechnology

Alivus Life Sciences Ltd Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,268.6P/E: 25.0Market Cap: ₹15.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 4

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Glenmark Life Sciences expects high single-digit growth in Glenmark Pharma (GPL) business from FY '24 base.
Overall FY '25 top-line growth is projected at low to mid-teens, supported by a robust external business and expected recovery in the Japanese market.
Volume growth is anticipated around 10% to 11% with a price erosion of approximately 4% to 4.5%.
The CDMO segment is expected to see revenue growth, with plans to increase the portfolio, aiming for about INR 500-600 crores in 4 years and potentially INR 1,000 crores longer term.
Capacity expansions at Ankleshwar and Dahej operational beginning Q1 FY '25 will support growth.
The high-potency API pipeline (with 17 APIs and a $37 billion addressable market) will contribute significantly starting about 2 years from now.
Despite some Q4 delays due to geopolitical issues and policy alignment, order books remain strong, supporting growth outlook.

Margin guidance

Category 4

Glenmark Life Sciences expects overall revenue growth in FY '25 to be low to mid-teens percentage, driven by a high single-digit growth in Glenmark business (Generic API) and robust external business including CDMO and Japan market recovery.
EBITDA margins are projected in the range of 28% to 30%, considering a 100-150 basis points reduction due to discontinuation of PLI benefits.
The company anticipates volume growth of around 10-11%, with a price erosion of 4-4.5%.
One-time employee bonus costs, which impacted FY '24 margins, are expected to normalize from Q1 FY '25 onward.
Capacity expansions in Ankleshwar and Dahej starting FY '25 Q1 and subsequent phased additions are expected to support future growth.
The company foresees stable profitability with adjusted EBITDA margins around 31.8% after one-time adjustments in FY '24.

See what Alivus Life Sciences Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No explicit mention of any new fundraising through debt or equity in the transcript.
The company remains a net debt free company as of March 31, 2024.
There is mention of increased growth capital available with the new promoter Nirma Limited, but this refers to internal capital allocation rather than external fundraising.
Capex plans are underway, with INR129 crores spent in FY '24 and new capacities starting operations in FY '25.
Management focuses on calibrated capacity expansion based on business visibility, using existing resources.
No indications or plans disclosed for raising funds through debt or equity in the near future.

Order book

Yes

Glenmark Life Sciences reports a strong order book for the coming quarters despite recent supply chain disruptions.
Demand across most markets remains stable, with the exception of Japan, where inventory destocking is ongoing but expected to recover in H2 FY'25.
The company anticipates robust growth in both Generic API and CDMO businesses supported by new capacity additions.
There is no explicit quantification of the exact pending order value disclosed in the call.
Business visibility typically spans 1 to 2 quarters, allowing capacity to be scaled within approximately 5-6 months when new business arises.
The company is actively managing supply chain challenges caused by the Red Sea crisis to fulfill orders timely.
Overall, the outlook remains positive with strong order inflows and growth capital available for expansion.

See what Alivus Life Sciences Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

FY '25 Capex: Around INR340 crores planned.
Major part (~INR140 crores) allocated for greenfield site development at Sholapur.
Remaining capex to complete brownfield projects at Ankleshwar and Dahej.
Regular maintenance, R&D, and quality-related capex also included.
Capacity additions planned: ~208 KL at Ankleshwar (Plant 18), ~35 KL in pharma area 4 at Dahej.
Sholapur capacity (approx. 500 KL) expected by late FY '26, with phased commissioning.
Potential additional 120 KL capacity from Plant 6 in Dahej by mid-2026.
Investments targeted at technologies to open higher-value portfolio opportunities with commercialization expected in 2-3 years.
Strategy includes calibrated capacity expansion triggered by business visibility, enabling capacity buildout within 5-6 months if needed.
Increased growth capital with new promoter Nirma to support expansion and new initiatives.

Track Alivus Life Sciences Ltd — get its next earnings analysis in your feed

How does Alivus Life Sciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAlivus Life Sciences Ltd

Rev 3Mar 4

See where Alivus Life Sciences Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Alivus Life Sciences Ltd rank in Pharmaceuticals & Biotechnology?

Compare Alivus Life Sciences Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Alivus Life Sciences Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Bajaj Healthcare (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
Himalaya Nutravedics (Q2 FY27)
Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). Key investor prese
Granules India (Q2 FY27)
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…
Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →